About Nano Imrad Technology (NIT)
NIT is a medical research and development company. Our products include diagnostic imaging and therapeutic medical isotopes. Our core technology is immune labeled radionuclide nanoparticles.
We are offering Actinium-225 in millicurie quantities, beginning in the second quarter of 2023.
Theranostic immunolabled radiopharmaceuticals for prostate and breast cancer will be ready for Phase I Clinical trials third quarter of 2023 pending Health Canada, FDA, MHRA (Medicines and Healthcare products Regulatory Agency-UK), and Israel (Ministry of Health (MOH) Pharmaceutical Administration) approvals. Theranostic radiopharmaceuticals are in our pipline for colon, and lung cancers.
Actinium is a radioactive metal that is used in the field of cancer treatment, specifically as an aid in radiation therapy. It is a naturally occurring element, found in uranium ore, and can be produced synthetically in a laboratory environment. Learn More about Actinium-225
We will be making Actinium-225 available to licensed researchers, research institutions and clinicians who are looking to use Actinium-225 for research or treatments. For more information, please contact us.